The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial-Reference-Cited by-同舟云学术

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

Published:2019-10 Issue:5 Volume:8 Page:575-583
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl. Lung Cancer Res.

Author:

Wang Lili,He Zhen,Yang Sen,Tang Hong,Wu Yufeng,Li Shaomei,Han Baohui,Li Kai,Zhang Li,Shi Jianhua,Wang Zhehai,Cheng Ying,He Jianxing,Shi Yuankai,Chen Weiqiang,Luo Yi,Wu Lin,Wang Xiuwen,Nan Kejun,Jin Faguang,Dong Jian,Li Baolan,Sun Yan,Wang Qiming

Publisher

AME Publishing Company

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials;Medicine;2024-07-05

3. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study;International Journal of General Medicine;2023-09

4. Anlotinib: A Novel Molecular-Targeted Drug for Tumours;Journal of Biomedical Nanotechnology;2023-06-01

5. Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment;OncoTargets and Therapy;2022-10